TrialHaematologica2021

Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia.

Kerry A Rogers et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.